Vaccinex Chairs Featured Research Session 'Alzheimer's Therapy: Mechanisms Beyond Amyloid' at AAIC 2026 in London on Monday July 13 (9:00-10:30 AM BST), Presenting Phase 1b/2 SIGNAL-AD Data Titled 'Glial Biomarkers Associated With Disease Progression Are Regulated By SEMA4D Blocking Antibody Pepinemab in Patients With Early-Stage AD' Alongside Plans for the Expanded Randomized Phase 2b SIGNAL-AD2 Study; Elizabeth Evans, PhD (COO and Senior VP Discovery and Translational Medicine) Chairs and Presents
Vaccinex (NASDAQ: VCNX) presented new biomarker data from the Phase 1b/2 SIGNAL-AD trial of pepinemab, a humanized IgG4 monoclonal antibody targeting Semaphorin 4D (SEMA4D), at AAIC 2026 in London on Monday July 13, 2026 from 9:00-10:30 AM London time at ExCeL London. Elizabeth Evans, PhD, Chief Operating Officer and Senior VP of Discovery and Translational Medicine, chaired the Featured Research Session 'Alzheimer's therapy: mechanisms beyond amyloid' and presented results titled 'Glial Biomarkers Associated With Disease Progression Are Regulated By SEMA4D Blocking Antibody Pepinemab in Patients With Early-Stage AD.' The presentation showed that SEMA4D blockade regulates glial biomarkers associated with disease progression in early Alzheimer's disease, supporting the mechanistically distinct approach of targeting neuroinflammation and reactive astrocytes rather than amyloid or tau directly. Vaccinex outlined plans for an enlarged Phase 2b SIGNAL-AD2 study to test the intervention at scale.